This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Givlaari (givosiran)
General Description:
Givlaari (givosiran) is a small interfering RNA (siRNA) therapeutic used for the treatment of adult patients and children aged 12 years and older with acute hepatic porphyria (AHP) — a rare, genetic metabolic disorder that affects the production of heme, an essential component of hemoglobin.
Givlaari works by targeting and reducing the production of aminolevulinic acid synthase 1 (ALAS1) mRNA in the liver, thereby decreasing the accumulation of toxic heme intermediates that cause the symptoms and attacks associated with AHP. By lowering these toxins, Givlaari helps prevent attacks, reduce chronic pain, and improve the quality of life for individuals living with this condition.
Disease Indications:
Acute Hepatic Porphyria (AHP)
Manufacturer:
Alnylam Pharmaceuticals
Usage:
Subcutaneous Injection
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Pharmaceuticals and Medical Devices Agency (PMDA)
Package:
• Single-dose vial: 1 vial of 189 mg/mL
Shipping:
Cold Chain Shipping
Givlaari contains temperature-sensitive biological components that must be protected from heat, light, and improper handling. To ensure product stability and maintain its therapeutic potency, Givlaari is shipped under cold chain delivery conditions, using specialized medical couriers equipped with temperature-controlled packaging and vehicles.
Although cold chain shipping may involve higher costs than standard delivery, it guarantees that Givlaari remains safe, stable, and fully effective for patient administration.
How to Access Givlaari (givosiran) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Givlaari (givosiran) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in obtaining it legally through the Named Patient Program (NPP).
Here’s how the process works:
